{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:37:06Z","timestamp":1793079426626,"version":"4.5.0"},"reference-count":67,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0158","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:52:58Z","timestamp":1765781578000},"source":"Crossref","is-referenced-by-count":2,"title":["The diagnosis and treatment of stimulant-related emergencies"],"prefix":"10.3238","author":[{"given":"Alexa","family":"Fries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Nickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Spreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pilhatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"10.3238\/arztebl.m2025.0158_ref1","unstructured":"Rauschert A, M\u00f6ckl M, Seitz H, Wilms J, Olderbak S, Kraus L: Epidemiologischer Suchtsurvey. www.esa-survey.de\/ergebnisse\/querschnitt\/querschnitt-detailansicht\/illegale-drogen-2021\/ (last accessed on 10 April 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref2","unstructured":"EUDA – European Union Drugs Agency: Cocaine—the current situation in Europe (European Drug Report 2024). www.euda.europa.eu\/publications\/european-drug-report\/2024\/cocaine_en (last accessed on 16 April 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref3","unstructured":"EUDA – European Union Drugs Agency: Synthetic stimulants—the current situation in Europe (European Drug Report 2024). www.euda.europa.eu\/publications\/european-drug-report\/2024\/synthetic-stimulants_en (last accessed on 16 April 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref4","doi-asserted-by":"crossref","unstructured":"Quednow BB, D\u00fcrsteler K: Amphetamine und Crystal Meth: Epidemiologie, Symptomatik und Therapie konsumassoziierter St\u00f6rungen. PSYCH up2date 2022; 16: 381–97.","DOI":"10.1055\/a-1505-7708"},{"key":"10.3238\/arztebl.m2025.0158_ref5","unstructured":"Statistisches Bundesamt BfG: Gesundheitsberichtserstattung des Bundes. www.gbe-bund.de\/gbe\/isgbe.archiv?p_indnr=550&p_archiv_id=7056982&p_sprache=D&p_action=A (last accessed on 15 August 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref6","unstructured":"Suchthilfe in Deutschland 2023. Jahresbericht der Deutschen Suchthilfestatistik (DSHS). www.suchthilfestatistik.de\/fileadmin\/user_upload_dshs\/05_publikationen\/jahresberichte\/DSHS_DJ2023_Jahresbericht.pdf (last accessed on 17 April 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref7","doi-asserted-by":"crossref","unstructured":"Quednow BB, Herdener M: Kokain. In: Soyka M, Batra A, Moggi F, Walter M (eds.): Suchtmedizin. M\u00fcnchen: Elsevier 2025; 170–91.","DOI":"10.1016\/B978-3-437-21074-7.00011-3"},{"key":"10.3238\/arztebl.m2025.0158_ref8","doi-asserted-by":"crossref","unstructured":"Zimmermann U, Pietsch J: Psychische und Verhaltensst\u00f6rungen durch Amphetamine inkl. Methamphetamin und Methcathinon. In: Bauer M, Meyer-Lindenberg A, Kiefer F, Philipsen A, Adli M (eds.): Referenz Psychische St\u00f6rungen. Stuttgart: Georg Thieme Verlag 2021; 521–34.","DOI":"10.1055\/b-0041-181904"},{"key":"10.3238\/arztebl.m2025.0158_ref9","doi-asserted-by":"crossref","unstructured":"Cone EJ, Tsadik A, Oyler J, Darwin WD: Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit 1998; 20: 556–60.","DOI":"10.1097\/00007691-199810000-00019"},{"key":"10.3238\/arztebl.m2025.0158_ref10","doi-asserted-by":"crossref","unstructured":"Heinz A, Halil MG, Gutwinski S, Beck A, Liu S: ICD-11: \u00c4nderungen der diagnostischen Kriterien der Substanzabh\u00e4ngigkeit. Nervenarzt 2022; 93: 51–8.","DOI":"10.1007\/s00115-021-01071-7"},{"key":"10.3238\/arztebl.m2025.0158_ref11","doi-asserted-by":"crossref","unstructured":"Pierce RC, Kumaresan V: The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006; 30: 215–38.","DOI":"10.1016\/j.neubiorev.2005.04.016"},{"key":"10.3238\/arztebl.m2025.0158_ref12","doi-asserted-by":"crossref","unstructured":"Curran C, Byrappa N, McBride A: Stimulant psychosis: Systematic review. Br J Psychiatry 2004; 185: 196–204.","DOI":"10.1192\/bjp.185.3.196"},{"key":"10.3238\/arztebl.m2025.0158_ref13","doi-asserted-by":"crossref","unstructured":"Ersche KD, Williams GB, Robbins TW, Bullmore ET: Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol 2013; 23: 615–24.","DOI":"10.1016\/j.conb.2013.02.017"},{"key":"10.3238\/arztebl.m2025.0158_ref14","doi-asserted-by":"crossref","unstructured":"Bernhardt N, Petzold J, Gro\u00df C, et al.: Neurocognitive dysfunctions and their therapeutic modulation in patients with methamphetamine dependence: A pilot study. Front Psychiatry 2020; 11: 581.","DOI":"10.3389\/fpsyt.2020.00581"},{"key":"10.3238\/arztebl.m2025.0158_ref15","doi-asserted-by":"crossref","unstructured":"Scott JC, Woods SP, Matt GE, et al.: Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev 2007; 17: 275–97.","DOI":"10.1007\/s11065-007-9031-0"},{"key":"10.3238\/arztebl.m2025.0158_ref16","doi-asserted-by":"crossref","unstructured":"Wong AH, Crispino L, Parker JB, et al.: Characteristics and severity of agitation associated with use of sedatives and restraints in the emergency department. J Emerg Med 2019; 57: 611–9.","DOI":"10.1016\/j.jemermed.2019.07.019"},{"key":"10.3238\/arztebl.m2025.0158_ref17","doi-asserted-by":"crossref","unstructured":"Miner JR, Klein LR, Cole JB, Driver BE, Moore JC, Ho JD: The characteristics and prevalence of agitation in an urban county emergency department. Ann Emerg Med 2018; 72: 361–70.","DOI":"10.1016\/j.annemergmed.2018.06.001"},{"key":"10.3238\/arztebl.m2025.0158_ref18","doi-asserted-by":"crossref","unstructured":"Christ M, Grossmann F, Winter D, Bingisser R, Platz E: Modern triage in the emergency department. Dtsch Arztebl Int 2010; 107: 892–8.","DOI":"10.3238\/arztebl.2010.0892"},{"key":"10.3238\/arztebl.m2025.0158_ref19","unstructured":"Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP, Expert Consensus Panel for Behavioral E: The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11 Suppl 1: 5–108; quiz 10–2."},{"key":"10.3238\/arztebl.m2025.0158_ref20","doi-asserted-by":"crossref","unstructured":"Aljohani B, Burkholder J, Tran QK, Chen C, Beisenova K, Pourmand A: Workplace violence in the emergency department: A systematic review and meta-analysis. Public Health 2021; 196: 186–97.","DOI":"10.1016\/j.puhe.2021.02.009"},{"key":"10.3238\/arztebl.m2025.0158_ref21","doi-asserted-by":"crossref","unstructured":"Geoffrion S, Hills DJ, Ross HM, et al.: Education and training for preventing and minimizing workplace aggression directed toward healthcare workers. Cochrane Database Syst Rev 2020; 9: CD011860.","DOI":"10.1002\/14651858.CD011860.pub2"},{"key":"10.3238\/arztebl.m2025.0158_ref22","unstructured":"Jenner L: Management of patients with psychostimulant toxicity: Guidelines for emergency departments. Australian Government Department of Health and Ageing; 2006."},{"key":"10.3238\/arztebl.m2025.0158_ref23","doi-asserted-by":"crossref","unstructured":"Li MJ, Shoptaw SJ: Clinical management of psychostimulant withdrawal: Review of the evidence. Addiction 2023; 118: 750–62.","DOI":"10.1111\/add.16093"},{"key":"10.3238\/arztebl.m2025.0158_ref24","doi-asserted-by":"crossref","unstructured":"Clinical Guideline Committee (CGC) Members; ASAM Team; AAAP Team; IRETA Team: The ASAM\/AAAP Clinical practice guideline on the management of stimulant use disorder. J Addict Med 2024; 18: 1–56.","DOI":"10.1097\/ADM.0000000000001299"},{"key":"10.3238\/arztebl.m2025.0158_ref25","doi-asserted-by":"crossref","unstructured":"Trivedi MH, Walker R, Ling W, et al.: Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med 2021; 384: 140–53.","DOI":"10.1056\/NEJMoa2020214"},{"key":"10.3238\/arztebl.m2025.0158_ref26","doi-asserted-by":"crossref","unstructured":"Ronsley C, Nolan S, Knight R, et al.: Treatment of stimulant use disorder: A systematic review of reviews. PLoS One 2020; 15: e0234809.","DOI":"10.1371\/journal.pone.0234809"},{"key":"10.3238\/arztebl.m2025.0158_ref27","doi-asserted-by":"crossref","unstructured":"AshaRani PV, Hombali A, Seow E, Ong WJ, Tan JH, Subramaniam M: Non-pharmacological interventions for methamphetamine use disorder: A systematic review. Drug Alcohol Depend 2020; 212: 108060.","DOI":"10.1016\/j.drugalcdep.2020.108060"},{"key":"10.3238\/arztebl.m2025.0158_ref28","doi-asserted-by":"crossref","unstructured":"De Crescenzo F, Ciabattini M, D‘Alo GL, et al.: Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS Med 2018; 15: e1002715.","DOI":"10.1371\/journal.pmed.1002715"},{"key":"10.3238\/arztebl.m2025.0158_ref29","doi-asserted-by":"crossref","unstructured":"Jha MK, Ghitza UE, Shoptaw S, et al.: Early change in depressive symptom severity with naltrexone-bupropion combination and its association with reduction in methamphetamine use in ADAPT-2 Trial. J Clin Psychiatry 2025; 86: 25m15825.","DOI":"10.4088\/JCP.25m15825"},{"key":"10.3238\/arztebl.m2025.0158_ref30","doi-asserted-by":"crossref","unstructured":"Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D: Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. J Gen Intern Med 2019; 34: 2858–73.","DOI":"10.1007\/s11606-019-05074-8"},{"key":"10.3238\/arztebl.m2025.0158_ref31","doi-asserted-by":"crossref","unstructured":"Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M: Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010: CD007024.","DOI":"10.1002\/14651858.CD007024.pub2"},{"key":"10.3238\/arztebl.m2025.0158_ref32","doi-asserted-by":"crossref","unstructured":"Amin-Esmaeili M, Farokhnia M, Susukida R, et al.: Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction 2024; 119: 833–43.","DOI":"10.1111\/add.16409"},{"key":"10.3238\/arztebl.m2025.0158_ref33","doi-asserted-by":"crossref","unstructured":"Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM: Prescription psychostimulants for the treatment of stimulant use disorder: A systematic review and meta-analysis. Psychopharmacology (Berl) 2020; 237: 2233–55.","DOI":"10.1007\/s00213-020-05563-3"},{"key":"10.3238\/arztebl.m2025.0158_ref34","doi-asserted-by":"crossref","unstructured":"Roppolo LP, Morris DW, Khan F, et al.: Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (best practices in the evaluation and treatment of agitation). J Am Coll Emerg Physicians Open 2020; 1: 898–907.","DOI":"10.1002\/emp2.12138"},{"key":"10.3238\/arztebl.m2025.0158_ref35","doi-asserted-by":"crossref","unstructured":"Wodarz N, Krampe-Scheidler A, Christ M, et al.: Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity. Pharmacopsychiatry 2017; 50: 87–95.","DOI":"10.1055\/s-0042-123752"},{"key":"10.3238\/arztebl.m2025.0158_ref36","unstructured":"Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP, Expert Consensus Panel for Behavioral Emergencies: The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad Med 2001: 1–88; quiz 89–90."},{"key":"10.3238\/arztebl.m2025.0158_ref37","unstructured":"Bundeskriminalamt: Rauschgiftkriminalit\u00e4t: Bundeslagebild 2023. www.bka.de\/DE\/AktuelleInformationen\/StatistikenLagebilder\/Lagebilder\/Rauschgiftkriminalitaet\/2023\/BLB_RG_2023.html?nn=27972 (last accessed on 2 May 2025)."},{"key":"10.3238\/arztebl.m2025.0158_ref38","doi-asserted-by":"crossref","unstructured":"Milin S, Kleinau C, L\u00fcdorf T, et al.: Konsummotive bei Stimulanzienkonsum. Suchttherapie 2016; 17: 17–21.","DOI":"10.1055\/s-0041-111253"},{"key":"10.3238\/arztebl.m2025.0158_ref39","doi-asserted-by":"crossref","unstructured":"Voce A, Calabria B, Burns R, Castle D, McKetin R: A systematic review of the symptom profile and course of methamphetamine-associated psychosis. Subst Use Misuse 2019; 54: 549–59.","DOI":"10.1080\/10826084.2018.1521430"},{"key":"10.3238\/arztebl.m2025.0158_ref40","doi-asserted-by":"crossref","unstructured":"Rothman RB, Partilla JS, Dersch CM, Carroll FI, Rice KC, Baumann MH: Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction. Ann N Y Acad Sci 2000; 914: 71–81.","DOI":"10.1111\/j.1749-6632.2000.tb05185.x"},{"key":"10.3238\/arztebl.m2025.0158_ref41","doi-asserted-by":"crossref","unstructured":"Volkow ND, Chang L, Wang GJ, et al.: Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21: 9414–8.","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001"},{"key":"10.3238\/arztebl.m2025.0158_ref42","unstructured":"Moritz F, Bauer F, Boyer A, et al.: [Patients in a state of agitation at the admission service of a Rouen hospital emergency department]. Presse Med 1999; 28: 1630–4."},{"key":"10.3238\/arztebl.m2025.0158_ref43","doi-asserted-by":"crossref","unstructured":"Amanollahi A, Babeveynezhad T, Sedighi M, et al.: Incidence of rhabdomyolysis occurrence in psychoactive substances intoxication: A systematic review and meta-analysis. Sci Rep 2023; 13: 17693.","DOI":"10.1038\/s41598-023-45031-4"},{"key":"10.3238\/arztebl.m2025.0158_ref44","doi-asserted-by":"crossref","unstructured":"Westover AN, McBride S, Haley RW: Stroke in young adults who abuse amphetamines or cocaine: A population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64: 495–502.","DOI":"10.1001\/archpsyc.64.4.495"},{"key":"10.3238\/arztebl.m2025.0158_ref45","doi-asserted-by":"crossref","unstructured":"Schwartz BG, Rezkalla S, Kloner RA: Cardiovascular effects of cocaine. Circulation 2010; 122: 2558–69.","DOI":"10.1161\/CIRCULATIONAHA.110.940569"},{"key":"10.3238\/arztebl.m2025.0158_ref46","doi-asserted-by":"crossref","unstructured":"Gates DM, Ross CS, McQueen L: Violence against emergency department workers. J Emerg Med 2006; 31: 331–7.","DOI":"10.1016\/j.jemermed.2005.12.028"},{"key":"10.3238\/arztebl.m2025.0158_ref47","doi-asserted-by":"crossref","unstructured":"Chan P, Chen JH, Lee MH, Deng JF: Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J Toxicol Clin Toxicol 1994; 32: 147–55.","DOI":"10.3109\/15563659409000444"},{"key":"10.3238\/arztebl.m2025.0158_ref48","doi-asserted-by":"crossref","unstructured":"Kongsakon R, Papadopoulos KI, Saguansiritham R: Mirtazapine in amphetamine detoxification: A placebo-controlled pilot study. Int Clin Psychopharmacol 2005; 20: 253–6.","DOI":"10.1097\/01.yic.0000166815.83017.d8"},{"key":"10.3238\/arztebl.m2025.0158_ref49","doi-asserted-by":"crossref","unstructured":"McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM: Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008; 35: 334–42.","DOI":"10.1016\/j.jsat.2007.12.003"},{"key":"10.3238\/arztebl.m2025.0158_ref50","doi-asserted-by":"crossref","unstructured":"Srisurapanont M, Jarusuraisin N, Jittiwutikan J: Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry 1999; 33: 94–8.","DOI":"10.1046\/j.1440-1614.1999.00518.x"},{"key":"10.3238\/arztebl.m2025.0158_ref51","doi-asserted-by":"crossref","unstructured":"Thompson RG Jr., Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ: Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. J Psychopharmacol 2021; 35: 1420–30.","DOI":"10.1177\/02698811211050563"},{"key":"10.3238\/arztebl.m2025.0158_ref52","doi-asserted-by":"crossref","unstructured":"Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J: Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial. Am J Psychiatry 2008; 165: 1442–8.","DOI":"10.1176\/appi.ajp.2008.08020304"},{"key":"10.3238\/arztebl.m2025.0158_ref53","doi-asserted-by":"crossref","unstructured":"Liang Y, Wang L, Yuan TF: Targeting withdrawal symptoms in men addicted to methamphetamine with transcranial magnetic stimulation: A randomized clinical trial. JAMA Psychiatry 2018; 75: 1199–201.","DOI":"10.1001\/jamapsychiatry.2018.2383"},{"key":"10.3238\/arztebl.m2025.0158_ref54","doi-asserted-by":"crossref","unstructured":"Campbell J, Nickel EJ, Penick EC, et al.: Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict 2003; 12: 122–36.","DOI":"10.1080\/10550490390201380"},{"key":"10.3238\/arztebl.m2025.0158_ref55","doi-asserted-by":"crossref","unstructured":"Li MJ, Chau B, Belin T, et al.: Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction 2024; 119: 1840–5.","DOI":"10.1111\/add.16529"},{"key":"10.3238\/arztebl.m2025.0158_ref56","doi-asserted-by":"crossref","unstructured":"Sarkar S, Bhatia G, Dhawan A: Clinical practice guidelines for assessment and management of patients with substance intoxication presenting to the emergency department. Indian J Psychiatry 2023; 65: 196–211.","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_490_22"},{"key":"10.3238\/arztebl.m2025.0158_ref57","doi-asserted-by":"crossref","unstructured":"Holstege CP, Borek HA: Toxidromes. Crit Care Clin 2012; 28: 479–98.","DOI":"10.1016\/j.ccc.2012.07.008"},{"key":"10.3238\/arztebl.m2025.0158_ref58","doi-asserted-by":"crossref","unstructured":"Shukla L, Ghadigaonkar DS, Murthy P: Poisoning with drugs of abuse: Identification and management. Indian J Crit Care Med 2019; 23: S296–S304.","DOI":"10.5005\/jp-journals-10071-23309"},{"key":"10.3238\/arztebl.m2025.0158_ref59","doi-asserted-by":"crossref","unstructured":"Orsini J, Din N, Elahi E, et al.: Clinical and epidemiological characteristics of patients with acute drug intoxication admitted to ICU. J Community Hosp Intern Med Perspect 2017; 7: 202–7.","DOI":"10.1080\/20009666.2017.1356189"},{"key":"10.3238\/arztebl.m2025.0158_ref60","doi-asserted-by":"crossref","unstructured":"Freund Y, Viglino D, Cachanado M, et al.: Effect of noninvasive airway management of comatose patients with acute poisoning: A randomized clinical trial. JAMA 2023; 330: 2267–74.","DOI":"10.1001\/jama.2023.24391"},{"key":"10.3238\/arztebl.m2025.0158_ref61","doi-asserted-by":"crossref","unstructured":"Omidvari S, Azimzadeh Z, Rashnoo F, et al.: Molecular mechanisms and treatment strategies for methamphetamine-induced neurodegeneration, inflammation and neurotoxicity. Acta Neurobiol Exp (Wars) 2023; 83: 414–31.","DOI":"10.55782\/ane-2023-2488"},{"key":"10.3238\/arztebl.m2025.0158_ref62","doi-asserted-by":"crossref","unstructured":"Roque Bravo R, Faria AC, Brito-da-Costa AM, et al.: Cocaine: An updated overview on chemistry, detection, biokinetics, and pharmacotoxicological aspects including abuse pattern. Toxins (Basel) 2022; 14: 278.","DOI":"10.3390\/toxins14040278"},{"key":"10.3238\/arztebl.m2025.0158_ref63","doi-asserted-by":"crossref","unstructured":"Ferr\u00e9 S: Caffeine and substance use disorders. J Caffeine Res. 2013; 3: 57–58.","DOI":"10.1089\/jcr.2013.0015"},{"key":"10.3238\/arztebl.m2025.0158_ref64","doi-asserted-by":"crossref","unstructured":"El-Hadedy N, El-Husseiny M: Evidence-based design for workplace violence prevention in emergency departments utilizing CPTED and space syntax analyses. HERD 2022; 15: 333–52.","DOI":"10.1177\/19375867211042902"},{"key":"10.3238\/arztebl.m2025.0158_ref65","unstructured":"D‘Ettorre G, Pellicani V, Mazzotta M, Vullo A: Preventing and managing workplace violence against healthcare workers in emergency departments. Acta Biomed 2018; 89: 28–36."},{"key":"10.3238\/arztebl.m2025.0158_ref66","doi-asserted-by":"crossref","unstructured":"Lenaghan PA, Cirrincione NM, Henrich S: Preventing emergency department violence through design. J Emerg Nurs 2018; 44: 7–12.","DOI":"10.1016\/j.jen.2017.06.012"},{"key":"10.3238\/arztebl.m2025.0158_ref67","doi-asserted-by":"crossref","unstructured":"Raveel A, Schoenmakers B: Interventions to prevent aggression against doctors: A systematic review. BMJ Open 2019; 9: e028465.","DOI":"10.1136\/bmjopen-2018-028465"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:53:20Z","timestamp":1765781600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":67,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0158","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}